Agile Therapeutics, Inc. (NASDAQ:AGRX) had its price objective lifted by Royal Bank Of Canada from $8.00 to $10.00 in a report published on Thursday, Marketbeat Ratings reports. Royal Bank Of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on AGRX. Janney Montgomery Scott restated a buy rating and issued a $15.00 price objective on shares of Agile Therapeutics in a report on Friday, July 21st. Noble Financial restated a buy rating on shares of Agile Therapeutics in a report on Sunday, July 30th. HC Wainwright assumed coverage on shares of Agile Therapeutics in a report on Wednesday, July 19th. They issued a buy rating and a $10.00 price objective on the stock. Finally, ValuEngine upgraded shares of Agile Therapeutics from a strong sell rating to a sell rating in a report on Saturday, July 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $9.08.

Agile Therapeutics (AGRX) opened at 3.83 on Thursday. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $7.95. The company has a 50-day moving average of $3.56 and a 200 day moving average of $3.45. The company’s market cap is $110.33 million.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm posted ($0.29) EPS. On average, equities analysts forecast that Agile Therapeutics will post ($1.02) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/18/agile-therapeutics-inc-agrx-given-new-10-00-price-target-at-royal-bank-of-canada.html.

In other news, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 25th. The shares were purchased at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 3.50% of the company’s stock.

Large investors have recently bought and sold shares of the company. Janney Montgomery Scott LLC purchased a new stake in shares of Agile Therapeutics during the second quarter valued at approximately $122,000. Royce & Associates LP grew its holdings in shares of Agile Therapeutics by 206.1% during the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares during the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Agile Therapeutics during the second quarter valued at approximately $205,000. Royal Bank of Canada grew its holdings in shares of Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Agile Therapeutics during the second quarter valued at approximately $309,000. Hedge funds and other institutional investors own 67.59% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.